Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
23 pending office actions • 14 art units • 23 examiners • 0 of 23 (0%) have an AI response strategy ready • 15 patents granted in the last 365 days
Children’S Hospital Medical Center has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, Emily Ann Cordas. The portfolio's current activity is limited to 1 distinct art unit, which indicates a very specific technical focus for this pending matter. Emily Ann Cordas is the busiest examiner, as she is responsible for the 1 pending office action.
Because there is only 1 pending office action, Emily Ann Cordas manages the entirety of the company's current pending workload. The concentration of the 1 pending office action within 1 distinct art unit means that prosecution is highly localized. Practitioners should tailor their approach to the specific standards of this 1 distinct art unit and the individual preferences of Emily Ann Cordas to successfully resolve the pending matter.
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (4%) |
| §101 + other | 3 (13%) |
| §103 only | 4 (17%) |
| §102 only | 2 (9%) |
| Double-patenting + other | 2 (9%) |
| Multi-statute (no §101) | 11 (48%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LARSEN, CARL VICTOR | 1 | 69.6% | +19.9% |
| MISHRA, DEEPA | 1 | 29.3% | +35.2% |
| MARVICH, MARIA | 1 | 54.9% | +28.1% |
| WILSON, MICHAEL C | 1 | 41.5% | +17.9% |
| LIPPOLIS, ALEXANDRA ROSE | 1 | 46.9% | +59.0% |
| AMICK, THOMAS RUSSE | 1 | 73.1% | +30.4% |
| ROGERS, ERIC JASON | 1 | 57.4% | +32.6% |
| STOICA, ELLY GERALD | 1 | 66.9% | +22.5% |
| MONTANARI, DAVID A | 1 | 64.7% | +49.0% |
| CHEN, STACY BROWN | 1 | 66.1% | +40.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17919030 | Systems and Methods for Quantification of Liver Fibrosis with MRI and Deep Learning | TIEU, BENNY QUOC | 121d overdue |
| 17421908 | COMPOSITIONS AND METHODS FOR TREATMENT OF A MALABSORPTIVE DISORDER | REGLAS, GILLIAN CHELSEA | 91d overdue |
| 18250996 | PSEUDOTYPED PARTICLES, MODIFIED CELLS, RELATED COMPOSITIONS, AND RELATED METHODS | O'NEILL, MARISOL ANN | 32d overdue |
| 18104055 | NPERSEVERE: BIOMARKERS ESTIMATING BASELINE MORTALITY RISK FOR NEONATAL SEPSIS AND NECROTIZING ENTEROCOLITIS | IVICH, FERNANDO NMN | 62d |
| 18915716 | METHODS FOR PREDICTING AUTOIMMUNITY POST GENE THERAPY | MISHRA, DEEPA | — |
| 18847004 | DELIVERY METHODS USING PLATELETS | MARVICH, MARIA | — |
| 18737201 | SELF-INACTIVATING LENTIVIRAL VECTOR ENCODING BETA- OR GAMMA-GLOBIN | WILSON, MICHAEL C | — |
| 18415949 | INTEIN TECHNOLOGY TO DELIVER ABCA3 LIPID TRANSPORTER FOR ABCA3 DEFICIENCY | LIPPOLIS, ALEXANDRA ROSE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18276905 | INFLUENZA VACCINE COMPOSITIONS AND METHODS OF USING SAME | CHEN, STACY BROWN | 63d |
| 19063450 | BIOMETRIC-BASED VIDEO GAME CONTROL SYSTEM AND METHODS THEREOF | LARSEN, CARL VICTOR | — |
| 18915716 | METHODS FOR PREDICTING AUTOIMMUNITY POST GENE THERAPY | MISHRA, DEEPA | — |
| 18847004 | DELIVERY METHODS USING PLATELETS | MARVICH, MARIA | — |
| 18737201 | SELF-INACTIVATING LENTIVIRAL VECTOR ENCODING BETA- OR GAMMA-GLOBIN | WILSON, MICHAEL C | — |
| 18415949 | INTEIN TECHNOLOGY TO DELIVER ABCA3 LIPID TRANSPORTER FOR ABCA3 DEFICIENCY | LIPPOLIS, ALEXANDRA ROSE | — |
| 18578381 | DIFFERENTIAL CXCR4 EXPRESSION ON HEMATOPOIETIC PROGENITOR CELLS VERSUS STEM CELLS DIRECTS HOMING AND LONG-TERM ENGRAFTMENT | AMICK, THOMAS RUSSE | — |
| 18573954 | STRUCTURALLY COMPLETE ORGANOIDS | ROGERS, ERIC JASON | — |
| Art Unit | Apps |
|---|---|
| 1638 | 3 |
| 1632 | 3 |
| 1633 | 2 |
| 1699 | 1 |
| 1647 | 1 |
| 1672 | 1 |
| 1626 | 1 |
| 1655 | 1 |
| 1758 | 1 |
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19063450 | BIOMETRIC-BASED VIDEO GAME CONTROL SYSTEM AND METHODS THEREOF | LARSEN, CARL VICTOR | — | §103 | Non-Final OA | — | Pending | Feb 26, 2025 |
| 18915716 | METHODS FOR PREDICTING AUTOIMMUNITY POST GENE THERAPY | MISHRA, DEEPA | — | §101§103§112 | Non-Final OA | — | Pending | Oct 15, 2024 |
| 18847004 | DELIVERY METHODS USING PLATELETS | MARVICH, MARIA | — | §102§103§112 | Non-Final OA | — | Pending | Sep 13, 2024 |
| 18737201 | SELF-INACTIVATING LENTIVIRAL VECTOR ENCODING BETA- OR GAMMA-GLOBIN | WILSON, MICHAEL C | 1638 | §103§112 | Non-Final OA | — | Pending | Jun 07, 2024 |
| 18415949 | INTEIN TECHNOLOGY TO DELIVER ABCA3 LIPID TRANSPORTER FOR ABCA3 DEFICIENCY | LIPPOLIS, ALEXANDRA ROSE | — | §103§112 | Non-Final OA | — | Pending | Jan 18, 2024 |
| 18578381 | DIFFERENTIAL CXCR4 EXPRESSION ON HEMATOPOIETIC PROGENITOR CELLS VERSUS STEM CELLS DIRECTS HOMING AND LONG-TERM ENGRAFTMENT | AMICK, THOMAS RUSSE | 1638 | §102 | Non-Final OA | — | Pending | Jan 11, 2024 |
| 18573954 | STRUCTURALLY COMPLETE ORGANOIDS | ROGERS, ERIC JASON | 1699 | §102§112 | Non-Final OA | — | Pending | Dec 22, 2023 |
| 18380877 | COMPOSITIONS AND METHODS FOR TREATMENT OF PEDIATRIC PAIN | STOICA, ELLY GERALD | 1647 | DPOther | Non-Final OA | — | Pending | Oct 17, 2023 |
| 18473619 | COLONIC ORGANOIDS AND METHODS OF MAKING AND USING SAME | MONTANARI, DAVID A | 1632 | §101§103Other | Non-Final OA | — | Pending | Sep 25, 2023 |
| 18276905 | INFLUENZA VACCINE COMPOSITIONS AND METHODS OF USING SAME | CHEN, STACY BROWN | 1672 | §102§103§112DPOther | Final Rejection | 63d | Pending | Aug 11, 2023 |
| 18224632 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HPV-ASSOCIATED DISEASE STATES | HAVLIN, ROBERT H | 1626 | §102§103§112 | Non-Final OA | — | Pending | Jul 21, 2023 |
| 18333934 | Microspheres Containing Decellularized Donor Tissue and Their Use in Fabricating Polymeric Structures | BOECKELMAN, JACOB A | 1655 | §103 | Non-Final OA | 62d | Pending | Jun 13, 2023 |
| 18039391 | ENHANCED NANOPARTICLE DELIVERY SYSTEMS | KELLY, ROBERT M | 1638 | §102 | Non-Final OA | — | Pending | May 30, 2023 |
| 18252813 | REFINED USES OF GABA A RECEPTOR MODULATORS IN TREATMENT OF FRAGILE X SYNDROME | WHITE, DENNIS MICHAEL | 1758 | §102§103Other | Final Rejection | — | Pending | May 12, 2023 |
| 18250996 | PSEUDOTYPED PARTICLES, MODIFIED CELLS, RELATED COMPOSITIONS, AND RELATED METHODS | O'NEILL, MARISOL ANN | 1633 | §102§103 | Final Rejection | 32d overdue | Pending | Apr 28, 2023 |
| 18027900 | RAFT CULTURES AND METHODS OF MAKING THEREOF | MIANO, JOSEPH PAUL | 1631 | §103§112 | Final Rejection | — | Pending | Mar 22, 2023 |
| 18104055 | NPERSEVERE: BIOMARKERS ESTIMATING BASELINE MORTALITY RISK FOR NEONATAL SEPSIS AND NECROTIZING ENTEROCOLITIS | IVICH, FERNANDO NMN | 1678 | §103§112Other | Non-Final OA | 62d | Pending | Jan 31, 2023 |
| 17997264 | Precision Dosing Regimen | GU, QINHUA | 1633 | §103 | Non-Final OA | — | Pending | Oct 27, 2022 |
| 17919030 | Systems and Methods for Quantification of Liver Fibrosis with MRI and Deep Learning | TIEU, BENNY QUOC | 2682 | §101 | Non-Final OA | 121d overdue | Pending | Oct 14, 2022 |
| 17634148 | METHODS FOR MAKING ORGANOID COMPOSITIONS | BEHARRY, ZANNA MARIA | 1632 | §101§103§112Other | Non-Final OA | — | Pending | Feb 09, 2022 |
| 17627613 | METHOD OF TREATING NEOPLASTIC DISEASES WITH A CDC42-SPECIFIC INHIBITOR | PUTTLITZ, KARL J | 1646 | §103 | Final Rejection | — | Pending | Jan 14, 2022 |
| 17617165 | RATIONAL THERAPEUTIC TARGETING OF ONCOGENIC IMMUNE SIGNALING STATES IN MYELOID MALIGNANCIES VIA THE UBIQUITIN CONJUGATING ENZYME UBE2N | PATTERSON, SARAH COOPER | 1675 | §103§112 | Non-Final OA | — | Pending | Dec 07, 2021 |
| 17421908 | COMPOSITIONS AND METHODS FOR TREATMENT OF A MALABSORPTIVE DISORDER | REGLAS, GILLIAN CHELSEA | 1632 | §103§112 | Non-Final OA | 91d overdue | Pending | Jul 09, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial